The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes.

Abstract

OBJECTIVE:

The aim of this study was to examine the effects of rosiglitazone on adiponectin and plasma glucose levels in relation with common adiponectin gene (ACDC) polymorphisms.

RESEARCH DESIGN AND METHODS:

A total of 166 patients with type 2 diabetes were treated with rosiglitazone (4 mg/day) for 12 weeks without changing any of their previous medications. In all, single nucleotide polymorphism (SNP)45 and SNP276 of ACDC were examined.

RESULTS:

Regarding SNP45, there was a smaller reduction in the fasting plasma glucose (FPG) level and the HbA(1c) value in the carriers of the GG genotype than in the carriers of the other genotypes (P = 0.031 and 0.013, respectively). There was a smaller increase in the serum adiponectin concentration for the GG genotype than for the other genotypes (P = 0.003). Regarding SNP276, there was less reduction in the FPG level for the GG genotype than for the other genotypes (P = 0.001). In the haplotype analysis, the reductions in the FPG and HbA(1c) levels were smaller for the GG homozygote haplotype than for the other haplotypes (P = 0.001 and 0.001, respectively). The increase in the plasma adiponectin concentration for the GG homozygote haplotype was smaller than that of the other haplotypes (P = 0.003).

CONCLUSIONS:

These data suggest that genetic variations in the adiponectin gene can affect the rosiglitazone treatment response of the circulating adiponectin level and blood glucose control in type 2 diabetic patients.

• Authors: Eun Seok Kang, So Young Park, Hyeong Jin Kim, Chul Woo Ahn, Moonsuk Nam, Bong Soo Cha, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee
• Journal: Diabetes care (Diabetes Care) Vol. 28 Issue 5 Pg. 1139-44 (May 2005) ISSN: 0149-5992 [Print] United States
• PMID: 15855579 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Adiponectin
• Hypoglycemic Agents
• Intercellular Signaling Peptides and Proteins
• Thiazolidinediones
• Rosiglitazone

Topics

• Adiponectin
• Aged
• Diabetes Mellitus, Type 2 (drug therapy, genetics)
• Drug Resistance (genetics)
• Female
• Haplotypes
• Homozygote
• Humans
• Hypoglycemic Agents (therapeutic use)
• Intercellular Signaling Peptides and Proteins (genetics)
• Male
• Middle Aged
• Polymorphism, Single Nucleotide
• Promoter Regions, Genetic (genetics)
• Rosiglitazone
• Thiazolidinediones (therapeutic use)